Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

Kodiak Sciences Inc. (Nasdaq: KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR").

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and ...

According to Future Market Insight, the global diabetic retinopathy market is likely to reach USD 15.50 billion by 2033, registering a CAGR of 5.8%. This is a significant rise from the estimated value ...

Usha (name changed), 62, was experiencing sudden and painless loss of vision in the right eye for one day when she turned up ...

If there are signs of diabetic retinopathy, you will be advised to undergo certain tests and procedures. This may involve an ophthalmologist, a specialist in eye diseases. The first line of treatment ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Roche, Ainnova, and Salud 360 signed this alliance to improve access to vision screening in patients with uncontrolled diabetes.

Your treatment depends on what your ophthalmologist sees in your eyes. If you have mild or moderate non-proliferative diabetic retinopathy, you may not need treatment right away. Your ophthalmologist ...

Diabetes can affect many parts of the body, including the eyes. Routine eye exams can help identify the early stages of eye ...